The Department of Defense (DOD) is launching its first-ever clinical trial of MDMA-assisted therapy for active-duty service members with PTSD at Walter Reed National Military Medical Center. …funded via the Defense Appropriations Act, has a number of interesting features. Those include the use of D-amphetamine as a control, a combination of the Lykos Therapeutics model…
A recent study in the Journal of Psychoactive Drugs has shed light on a less discussed aspect of psychedelic experiences: the feelings of shame and guilt that can arise during these journeys. Mathai and his colleagues found that feelings of shame or guilt during psilocybin use were indeed common. Almost 70% of participants reported experiencing either shame…
…as people merge getting high and self-care… we need a new way to make sense of it. In today’s chaotic marketplace… the internet also transformed supply and demand… the idea of drugs as a social evil and the belief that only doctors define what is medical is being challenged… the distinction between licit “medicine” and…
…one study published in July 2024 found that the percentage of adults aged 35 to 50 who had used hallucinogens within the past year was seven times what it was in 2014. I spoke to a dozen women who use psychedelics regularly, and found them to be a diverse bunch: They come from different generations and…
In the mid-range of estimates, anywhere from 56% to 62% of Americans currently being treated for depression could be eligible to try psilocybin. The number could even grow higher if people currently untreated for their depression decide they would like to try psilocybin, the investigators noted. Original Article (Newsweek):Over 5 million Americans could benefit if psilocybin…
Psilocybin was supplied by Usona Institute… (Open Science and Praxis Signatories) here we tracked individual-specific brain changes with longitudinal precision functional mapping (roughly 18 magnetic resonance imaging visits per participant). Healthy adults were tracked before, during and for 3 weeks after high-dose psilocybin (25 mg) and methylphenidate (40 mg), and brought back for an additional psilocybin dose 6–12 months…
…if someone is desperate and suicidal, of course they should be able to try psychedelics, as quickly and safely as possible. The healthcare system is broken, the FDA approval system is slow and very expensive…and people can sometimes heal themselves outside of the medical system. Clusterbusters is a really interesting example of a peer support group which…
…it appears as though the owners of psilocybin shops have no plans to shut down for good. “This is like some kind of terrible drug war anachronism from some other era that shouldn’t even be on the books and we’re hopefully going to change that,” FunGuyz lawyer Paul Lewin. According to the former Ontario Provincial…
While psychedelics are sometimes portrayed in media as causing intense paranoia, particularly in a recreational setting, the study authors said psilocybin “was not associated with risk of paranoia and transient thought disorder.” The researchers identified five other reported adverse effects among certain patients in the clinical trials: headache, nausea, anxiety, dizziness and elevated blood pressure.…
…an LSD analog, L S D (Lysergide D-Tartrate) was given “breakthrough therapy” designation by the FDA for treating anxiety. …this analog… a tartrate salt form… called MM-120. A single oral administration (100 µg) of this psychelic analog, MM120, maintained a clinically and statistically significant reduction in symptoms compared to placebo at 12 weeks — with…
Recent Comments